Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Bromhexine is metabolized into Ambroxol (Schaefer 2007 p72).
Effectiveness of this drug has not been established (Prescrire 2017, INSALUD 2001).
Oral administration two to three times a day.
At latest update, relevant published data on excretion into breast milk were not found.
Because of high serum protein-binding capacity (AEMPS 2016), excretion into breast milk in significant amount is seemingly unlikely.
Its low oral bioavailability (AEMPS 2016)causes a poor absorption into infant's serum as from breast milk, except in prematures and in the early neonatal period in which intestinal absorption may be increased.
Known adverse reactions are rare and mild.
Secretion of Prolactin and other hormones have not been affected by taking this medication (Tuimala 1981).
Autores expertos lo consideran seguro durante la lactancia (Schaefer 2007 p644).
See below the information of this related product: